Alberto Bettinelli,
Nicolò Borsa,
Rosa Bellantuono,
Marie-Louise Syrèn,
Raffaele Calabrese,
Alberto Edefonti, John Komninos,
Marisa Santostefano,
Luciano Beccaria,
Ivana Pela,
Mario G Bianchetti,
Silvana Tedeschi
[show abstract]
[hide abstract]
ABSTRACT: Little information on the management and long-term follow-up of patients with biallelic mutations in the chloride channel gene CLCNKB is available.
Long-term follow-up was evaluated from 5.0 to 24 years (median, 14 years) after diagnosis in 13 patients with homozygous (n = 10) or compound heterozygous (n = 3) mutations.
Medical treatment at last follow-up control included supplementation with potassium in 12 patients and sodium in 2 patients and medical treatment with indomethacin in 9 patients. At the end of follow-up, body height was 2.0 standard deviation score or less in 6 patients; 2 of these patients had growth hormone deficiency. Body weight (<or=2.0 standard deviation score in 6 patients) significantly increased (P < 0.05) at the end of follow-up in comparison to values at diagnosis. Nonpostural persistent proteinuria was present in 6 patients, and 4 patients had a glomerular filtration rate less than 75 mL/min/1.73 m(2) (<1.25 mL/s).
These data show that some patients with biallelic mutations in the chloride channel gene CLCNKB tend to present with pathological proteinuria and impaired kidney function after a median follow-up of 14 years, and growth retardation is common and sometimes related to growth hormone deficiency in these patients.
American Journal of Kidney Diseases 01/2007; 49(1):91-8. · 5.43 Impact Factor
